STOCKS TELEGRAPH

Tag: JAGX

  • Jaguar Health Faces Steep Decline Amid Upcoming Reverse Stock Split

    Jaguar Health, Inc. (NASDAQ: JAGX) experienced a tumultuous trading session on Friday, witnessing a nearly 10% drop from $0.29 to $0.26. The situation worsened over the weekend, and by Monday’s premarket hours, the stock had plunged further to the $0.18 zone, reflecting a significant loss in investor confidence.

    Stock Performance and Volume Surge

    The substantial decline in Jaguar Health’s stock price was accompanied by an unprecedented surge in trading volume, with nearly 58 million shares changing hands. This volume spike was primarily driven by sellers offloading their shares, exacerbating the downward pressure on the stock.

    The sharp drop reflects market apprehension surrounding the company’s financial health and upcoming corporate actions.

    Company Overview and Reverse Stock Split

    Jaguar Health is a commercial-stage pharmaceuticals company engaged in developing gastrointestinal products, operating through Human Health and Animal Health segments.

    Its Human Health segment focuses on Mytesi, a product for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment deals with both prescription and non-prescription products for companion and production animals.

    A critical factor contributing to the recent stock performance is Jaguar Health’s history of significant share dilution. From 2022 to 2023, the number of outstanding shares skyrocketed from 2 million to 73 million.

    In an effort to address these concerns and comply with Nasdaq’s listing standards, Jaguar Health will implement a one-for-sixty reverse stock split on Thursday, May 23, 2024. This move aims to consolidate shares, reduce outstanding share counts, and make the stock more attractive to institutional investors.

    Conclusion

    As Jaguar Health braces for its reverse stock split, investors remain cautious. The split, approved at a Special Meeting of Stockholders, will see every sixty shares reclassified into one share without changing the par value. The company hopes this strategic move will bolster compliance with Nasdaq’s standards and restore investor confidence. Stockholders will receive instructions from Equiniti Trust Company, LLC on how to exchange their certificates post-split.

  • Jaguar Health (JAGX) Pre-market Surge Continues: Eyes on Elite Ped-GI Congress

    In an unprecedented move, Jaguar Health, Inc. (NASDAQ: JAGX) sustained its remarkable momentum from Thursday, catapulting another 21% in premarket trading on Friday. Investors are witnessing an astonishing rally, with signs pointing towards further gains throughout the day.

    This surge comes amidst a lack of immediate news catalysts, fueling speculation of a potential profit-taking dip in the near future. However, for now, bullish sentiment prevails, propelling JAGX to new heights.

    Company Profile and Recent Developments

    Jaguar Health, Inc. operates as a commercial-stage pharmaceuticals company, specializing in gastrointestinal products. Its Human Health segment focuses on manufacturing and promoting Mytesi, offering relief for non-infectious diarrhea in adults with HIV/AIDS.

    Meanwhile, the Animal Health segment is dedicated to providing prescription and non-prescription products for companion and production animals.

    This week, the company announced its sponsorship of the 10th Annual Elite Ped-GI Congress in Abu Dhabi, UAE, through its subsidiary, Napo Pharmaceuticals. The congress features a panel discussion, “Masterclass in Congenital Diarrhea,” spotlighting microvillus inclusion disease (MVID), a rare congenital disorder. Notably, Jaguar’s crofelemer, a plant-based prescription drug, has received Orphan Drug Designation from both the FDA and EMA for MVID and short bowel syndrome (SBS) with intestinal failure.

    Lisa Conte, President, and CEO of Jaguar Health, emphasized the company’s commitment to supporting investigator-initiated studies of crofelemer for rare diseases like MVID. These efforts aim to provide early patient access to crofelemer for debilitating conditions with limited treatment options.

    Expert Insights and Market Trends

    Dr. Mohamad Miqdady, a member of Napo’s Scientific Advisory Board, will moderate the panel discussion at the Elite Ped-GI Congress. Joining him are renowned experts, including Jaguar’s Chief Scientific Officer, Dr. Pravin Chaturvedi. The surge in trading volume, currently triple the average, underscores the market’s heightened interest in JAGX.

    Over the past month, JAGX has quadrupled in price, reflecting a trend likely to persist. As investors eagerly await updates from the Elite Ped-GI Congress, the spotlight remains on Jaguar Health, Inc. and its pioneering efforts in gastrointestinal therapeutics.

    Conclusion

    Jaguar Health, Inc.’s pre-market surge defies expectations, fueled by anticipation surrounding its participation in the Elite Ped-GI Congress. With promising developments in rare disease therapeutics, JAGX continues to capture the attention of investors, paving the way for future growth and innovation in the pharmaceutical industry.

  • Jaguar Health Inc. Rockets Upward Despite Nasdaq Listing Uncertainty

    The trading day on Friday saw Jaguar Health, Inc. (NASDAQ: JAGX) skyrocketing by an astounding 50%, followed by an additional 13% surge in after-hours trading. This unexpected surge has sparked speculation among market participants about its implications for the week ahead.

    Jaguar Health is a pharmaceutical company specializing in gastrointestinal products, operating in two segments: Human Health and Animal Health. Its flagship product, Mytesi, addresses diarrhea symptoms in adults with HIV/AIDS on antiretroviral therapy, setting it apart in the pharmaceutical industry.

    Market Dynamics and Concerns

    The surge in Jaguar Health’s stock was accompanied by an unprecedented spike in trading volume, reaching a remarkable 300 million shares traded, significantly higher than the average volume of below 13 million. This surge has raised concerns among some investors about a potential dip in profits without significant news catalysts.

    The spontaneous nature of the recent rise points a number of red flags regarding the sustainability of this jump. For this reason, many on the sidelines remain skeptical of this bullish rush.

    Delisting Update and Uncertainty

    Jaguar Health faces a delisting threat from Nasdaq due to its failure to meet the minimum bid price requirement. Although the company has requested a hearing to appeal, the outcome remains uncertain. Currently, Jaguar Health’s common stock trades under the symbol ‘JAGX,’ pending a final decision.

    Institutional Support and Long-Term Outlook

    Despite challenges, Jaguar Health has seen a steady increase in institutional holdings, indicating growing confidence among larger investors. This suggests underlying optimism regarding the company’s long-term prospects, despite market volatility.

    Conclusion

    In conclusion, while Jaguar Health’s recent stock performance has been impressive, caution is advised due to the lack of concrete news catalysts and uncertainty about its listing status.

    Nonetheless, the company’s unique product offerings and increasing institutional support provide reasons for cautious optimism amidst market turbulence. Investors should stay vigilant for developments in the coming days to gauge the stock’s trajectory.

  • Here is what you need to know about rising Jaguar Health, Inc. (JAGX) stock in Pre-Market today

    Here is what you need to know about rising Jaguar Health, Inc. (JAGX) stock in Pre-Market today

    Shares of the Jaguar Health, Inc. (JAGX) stock continued the rising trend in the pre-market trading session today on July 20, 2021. The momentum was created after the announcement of the closing of a financing of Dragon SPAC byDragon SPAC S.p.A. and Napo EU S.p.A, the Italian subsidiary of Napo Pharmaceuticals, which is a wholly-owned subsidiary of JAGX stock. Jaguar stock price saw a push of 8.28% to reach $1.57 a share at the time of this writing. The stock went high by 10.69% at the previous closing. Let’s take a closer look at recent events.

    Dragon SPAC Financing:

    The gross proceeds for the Dragon SPAC financing were totaled approximately 8,830,000 euros. This financing is the result of previously announced $10.8 million funding by the Jaguar stock into Dragon SPAC. The funds obtained from the recently registered direct offering were used in this financing. The net proceeds resulting from the private placement will be used to finance Dragon SPAC’s merger with Napo EU. Furthermore, the net proceeds would also help in financing the combined activities after the merging of Napo EU and Dragon SPAC. The merger is expected to be completed within the next three months.

    How Jaguar Health will help Napo EU:

    The Napo EU is dedicated to expanding its plant-based medicines in Europe in order to fulfill the gastrointestinal medical needs of the consumers. The JAGX stock will help Napo EU by providing the exclusive Napo license for the development and commercializing of Crofelemer in the European market.

    Completion of Phase 2 HALT-D study:

    On July 14, 2021, JAGX stock did announce the completion of the Phase 2 HALT-D study which was initiated by the third-party investigator. The study was related to the evaluation of the effectiveness of Mytesi®, a Crofelemer, against HER2-positive breast cancer patients in order to analyze the symptomatic relief in diarrhea. The Georgetown University sponsored the investigator and Genentech which is a member of Roche Group, did funding.

    JAGX annual shareholders’ meeting:

    Due to the lack of quorum, the annual shareholders’ meeting of JAGX had been adjourned for the third time and now will be held on August 6, 2021, at the San Francisco office. The record of the eligible JAGX stockholders for the annual meeting is April 12, 2021.

    Wrap Up:

    So far so good for JAGX stock as far as market sentiment is concerned. Crofelemer’s first-in-class mechanism would prove to be beneficial for the people and would make an impact in the future. Hence JAGX stock can be a good bet for investors in the long run.

  • Jaguar Health Inc. (JAGX) stock rises in the after-hour trading. Why is it so?

    Jaguar Health Inc. (JAGX) stock rises in the after-hour trading. Why is it so?

    Jaguar Health Inc. (JAGX) stock surged by 3.45% in the last trading closed as well as the JAGX stock continued to rise by 9.44% in the after-hour after Jaguar Health announced its full year 2020 financial results. Jaguar Health, the pharmaceutical company is dedicated towards developing innovative, plant-based, non-opioid, and sustainably derived pharmaceutical drugs for people and animals who are suffering from gastrointestinal distress, especially chronic, debilitating diarrhea. The Mytesi product is the only oral plant-based prescribed drug approved under FDA Botanical Guidelines for the effective treatment of noninfectious diarrhea in adults with HIV/AIDS who are on antiretroviral therapy.

    2020 Financial Results

    • For the year 2020 Mytesi net sales were around $9.3 million and Mytesi gross sales have been calculated as $20.4 million, this is an increase of 64% and 148% respectively compared to the previous year.
    • The net operating expense generated for the year 2020 was $36.0 million while it was $34.7 million for the year 2019. The operating has increased by 4% from the previous year.
    • JAGX’s total cost of product revenue was $3.3 million compared to $3.8 million from the year 2019 that means it is a decrease of 14%.
    • The General and Administrative expense was $14.4 million for the year 2020 whereas the G&A expense for the previous year was $13.5 million that means it has increased.
    • The R&D expense of JAGX stock for 2020 was $6.4 million, relative to $5.8 million in 2019, a rise of 10%, or $0.6 million, year over year. Other expenditures of $0.9 million, mostly consulting, formulation, and regulatory fees, contributed to the rise.
    • Lastly the net loss faced by JAGX stock for the year 2020 was $33.8 million which has also decreased relative to the previous year where net loss was $38.5 million.

    Other Recent Development

    On March 30, 2021, JAGX stock announced that it supports the main sponsor’s choice of investment bank and nominated advisor (“NOMAD”) for the proposed Dragon special purpose acquisition company. The Dragon SPAC plans to list on the AIM Italia exchange and merge with its named goal, Napo EU S.p.A. which is the Dragon SPAC’s Italian subsidiary.

    After the upcoming holidays, during the week of April 5th, more details on the Dragon SPAC’s banking engagement, including the Dragon SPAC’s selection of its necessary NOMAD, will be published. A NOMAD is a necessary financial services firm that will assist and help the issuer, the Dragon SPAC, in complying with Borsa Italiana’s IPO process for AIM Italia listing.

  • Jaguar Health (JAGX) Closes its M Promissory Notes, What’s Next for JAGX Stock?

    Jaguar Health (JAGX) Closes its $6M Promissory Notes, What’s Next for JAGX Stock?

    Jaguar Health has had swift growth in 2020 as the demand for its Mytesi continues to rise.

    The pharmaceutical firm has kicked off the new year in style. Jaguar Health (JAGX) stock soared over 265% in the first week of January. The early-year gains indicate that the penny stock has a long way to go in 2021. The bull run is directing towards a positive trajectory as we move ahead.

    Recently, the company announced that it has entered into a definitive agreement to sell its promissory notes worth $6 million to Streeterville Capital—investor. Also, there’s a notable development happening across its novel proprietary drug, Crofelemer. So, 2021 is going to be exciting for Jaguar Health’s stock.

    What’s Next?

    Jaguar Health is heading in the right direction. The company has been quite active recently. On Jan. 13, 2021, Jaguar announced the purchase agreement for the sale of its common stock shares to its institutional investors. Around 4,437,870 common stock shares were floated at a per-share price of $3.38 that would bring gross proceeds of almost $15 million.

    On the very same day, the company also announced a binding agreement of terms for $6 million backed by the sale of tropical disease priority review voucher. Jaguar’s subsidiary, Napo Pharmaceuticals intends to go for an incentive for the development of Napo’s lechlemer drug with the help of this priority review voucher.

    On Jan. 19, the company signed a definitive agreement to issue and sell its secured promissory note to Streeterville for a principal amount of $6 million. Jaguar reported that the sale of Note closed on Jan. 19, 2021.

    Following the promissory note sale, Streeterville has the right to 18% of the gross proceeds of the review voucher for lechlemer drug. Whereas, Jaguar can redeem the Note at a 12.5% premium after the 6-months—any time.

    Moreover, the company is working to obtain conditional marketing authorization in Europe for its novel proprietary drug, Crofelemer. The company wants to conduct the initial study on Crofelemer in a “long-hauler” COVID-19recovery patient population in Europe. Jaguar is looking to accelerate the development and commercialization of Crofelemer as it’s the need of the hour—once it obtains the regulatory approval.

    Jaguar Health has another strong product in the market that’s making a lot of revenue. Napo’s product, Mytesi® reported a net sale of almost $2.8 million in Q3 2020, an increase from $1 million in 2019.

    Conclusion

    Jaguar Health (JAGX) is well-position across different spaces and is making way for its new product, Crofelemer, in Europe. From a penny stock in 2020 to cross the $3 price mark this year, JAGX has shown serious promise. Investors are keeping an eye on the stock; it will be making moves this year. The average trading volume stands around 57.5 million, as we write this. So, some serious bulls are coming Jaguar’s way.

  • Early Morning Vibes: 4 Top Trending Stocks To Watch Right Now

    Early Morning Vibes: 4 Top Trending Stocks To Watch Right Now

    Trades on January 7, US stock indexes finished in the green zone, setting new all-time highs. The S&P 500 Index rose 1.48% to 3804 points, the Dow Jones added 0.69%, the NASDAQ rose 2.56%. Investors took advantage of the attractive weakness in growth stocks as concerns about a corporate tax hike eased. Macro statistics turned out to be better than expected, business activity in the services sector rose steadily in December. Against this background, the IT sector became the growth leader with a result of 2.65%.

    Corporate Updates

    Plug Power (PLUG: + 35.1%) has entered into a strategic partnership with SK Group, which is investing $1.5 billion in PLUG in exchange for a 9.9% stake.

    L Brands (LB: + 6%), which owns the Victoria’s Secret brand, reported strong sales over the holidays and raised its 4Q EPS forecast.

    Albemarle (ALB: + 5.1%) will double production in Nevada by 2025 to meet demand for lithium used in electric car batteries.

    Today, world stock exchanges are showing mostly positive dynamics. The news background is quite calm and no new drivers of movement are observed. Donald Trump has been criticized for supporting his supporters on social media, and senators are discussing the possibility of an earlier removal of the president from office. On a positive note, Trump is committed to a peaceful transfer of power to new President Joseph Biden. Investors remain focused on assessing Biden’s potential reforms under Congress with a slight Democratic lead. Expectations are generally positive, so risk appetite is increased. The focus of investors’ attention will gradually shift from the political arena to the real economy.

    According to the latest comments from representatives of the Federal Reserve, the pace of economic recovery in the first quarter will be minimal, there is a risk of GDP contraction. In this regard, today’s publication of the block of macro-statistics on the labor market, which may not meet expectations, is of interest.

    Economic Highlights

    Today will be published the change in the number of employed in the non-agricultural sector for December. Growth is expected by 71 thousand, which is much less than the previous – 245 thousand. Published on Wednesday, January 6, data from the ADP showed a decline in the number of employees, which may be reflected in today’s publication. Yesterday, the employment component of the service PMI showed weakness, falling below 50. All this indicates the risk of the unemployment rate rising in December from 6.7% to 6.8-7.0%.

    The Freedom Finance Sentiment Index climbed to 66 out of 100. The indicator reflects market participants’ hope for a global economic recovery in 2021. Worries about the negative impact of the coronavirus pandemic are starting to wane thanks to the prospect of mass vaccinations starting soon.

    Technical picture

    Technically, the S&P 500 still looks attractive, the trend remains strong. Buyers continue to demonstrate relative strength. At the same time, the index is approaching the overbought zone according to the RSI indicator, which may mean a quick slowdown in growth and, at least, consolidation. A fall below the 3640-support level will lead to a reversal of the short-term trend.

    Today Top Movers

    ‎Scworx Corp (WORX), a software solutions provider company for the management of health, soared about 48.73% ‎at $2.35 in pre-market trading Friday.‎‎ 

    ‎Jaguar Health Inc (JAGX) share price jumped 13.05% to $3.03 during early morning ‎trading session on Friday.‎ 

    ‎Ideanomics Inc (IDEX) stock ascended 7.38% at $3.20 in the pre-‎market trading today. The company recently signed a definitive agreement to acquire 100% of privately held Wireless Advanced Vehicle Electrification, Inc. for cash and stock consideration.‎

    ‎Future Fintech Group Inc (FTFT) increased over 36.35% at $7.84 in pre-market ‎trading on Friday following the declaration from the firm that on December 31, 2020, China Copyright Protection Center has accepted the Company’s application for ten software copyrights relating to blockchain technology applications.‎

    Top Upgrades & Downgrades

    Keefe, Bruyette & Woods turned bullish on Regions Financial Corporation (RF), upgrading the stock to “Outperform” and assigning a $18.5 price target, representing potential upside of 4.76% from Thursday’s close. 

    Tenet Healthcare Corporation (THC) has won the favor of Jefferies’s equity research team. The firm upgraded the shares from Hold to Buy and moved their price target to $60.0, suggesting 34.02% additional upside for the stock. 

    3M Company (MMM) received an upgrade from analysts at B of A Securities, who also set their one-year price target on the stock to $170.0. They changed their rating on MMM to Underperform from Neutral in a recently issued research note. 

    Earlier Friday RBC Capital reduced its rating on Taylor Morrison Home Corporation (TMHC) stock to Sector Perform from Outperform and assigned the price target to $27.0. With shares trading at around $25.78, the Wall Street firm thinks Taylor Morrison Home Corporation’s stock could add than 4.71%. 

    Evercore ISI Group analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Voya Financial Inc. (VOYA) has been changed to In-Line from Outperform and the new price target is set at $64. 

    Analysts at Needham downgraded Lam Research Corporation (LRCX)’s stock to Hold from Buy on Friday.

    Latest Insider Activity

    Capstone Turbine Corporation (CPST) Chief Financial Officer Hencken Frederick S. III announced the sale of shares taking place on Jan 05 at $10.69 for some 2,569 shares. The total came to more than $27463.

    Amazon.com Inc. (AMZN) Director RUBINSTEIN JONATHAN sold on Jan 05 a total 6,758 shares at $3166.01 on average. The insider’s sale generated proceeds of almost $0.99 million. 

    Blue Apron Holdings Inc. (APRN) 10% Owner DPH Holdings Ltd declared the purchase of shares taking place on Jan 04 at $5.63 for some 8,000 shares. The transaction amount was around $45040.

    Root Inc. (ROOT) 10% Owner Malka Meyer bought on Dec 30 a total of 1,753,976 shares at $16.55 on average. The purchase cost the insider an estimated $12.48 million.

    Important Earnings

    Top US earnings releases scheduled for Monday include Teligent Inc. (NASDAQ:TLGT). It will announce its Dec 2020 financial results. The company is expected to report earnings of -$1.27 per share from revenues of $15.45M in the three-month period. 

    Analysts expect Commercial Metals Company (NYSE: CMC) to report a net income (adjusted) of $0.54 per share when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Nov 2020 is predicted to come in at $1.34B.

  • Early Morning Vibes: 4 Stocks We Like for Tuesday Trading

    Early Morning Vibes: 4 Stocks We Like for Tuesday Trading

    Major US stock indices fell 1.3-1.5% on the first day of trading in 2021.

    The broad market S&P 500 index fell 1.48% to 3700.65 points, the industrial Dow Jones Industrial Average fell 1.25% to 30223.89 points, and the technological NASDAQ dropped 1.47% 12698.45 points.
     

    Despite the general optimistic sentiment of investors regarding the recovery of the global economy after the coronavirus pandemic, the indices declined.

    At the start of the new year, investors focused on the same issue that has dominated the markets for much of 2020: the coronavirus pandemic. Many expect economic activity to accelerate later this year as communities are vaccinated, and organizations reopened. At the same time, there is an understanding that the path to economic recovery will be long and uneven.

    Recent news on the coronavirus situation paints a bleak picture. In the United States, the number of hospitalizations on Sunday reached a record high. In several countries in Europe, governments are extending quarantine restrictions designed to slow the spread of infection.

    The difficulty in dealing with the pandemic means that many companies will be vulnerable to financial risks in the short term.

    The experts noted growing nervousness over the results of the second round of elections to the U.S. Senate in Georgia. The outcome of the vote will determine whether the Republicans will retain control of the Senate. According to investors in prediction markets, the likelihood of a GOP victory has diminished in the past few days, potentially signaling a tense battle for Senate seats.

    Corporate Highlights

    Coca-Cola shares lost 3.8%. RBC Capital Markets has downgraded their rating from “above sector” to “par with the sector.” The bank’s analysts believe that the pandemic will continue to restrict public events and consumer access to restaurants, negatively affecting demand for Coca-Cola products.

    Airline stocks, which were also seriously affected by the coronavirus, also declined on Monday. In particular, American Airlines shares fell 4.1%, while Delta Air Lines shares fell 3.7%.

    Hotel chain shares were also down, with Hilton Worldwide Holdings down 3.4%, while Marriott International shed 5.4%.

    Tesla, meanwhile, gained 3.4%. The electric vehicle maker said it delivered a record 499,550 vehicles last year, just slightly below its target of 500,000.

    Amid a massive sell-off in shares, gold prices jumped 2.7% to $ 1,944.70 per troy ounce, the most significant percentage gain since April. Precious metal quotes usually receive support when market volatility increases.

    An additional source of joy in the market was the latest data on the manufacturing sector’s state. According to surveys of purchasing managers, factories in Asia and Europe increased their output at the end of the year. In December, there was a substantial rise in activity.

    Today Top Movers

    ‎Jaguar Health Inc (JAGX) share price ascended 30.90% to $2.33 during early morning ‎trading session on Tuesday.‎ ‎

    Zosano Pharma Corp (ZSAN), a Biotechnology company, increased about 78.60% ‎at ‎‎$1.04 in pre-market trading Tuesday after declaring that the company requested a Type A meeting with the U.S. Food and Drug Administration (FDA) to review resubmission plans for Qtrypta new drug application. ‎

    Naked Brand Group Ltd (NAKD) stock surged 14.83% at $0.25 in the pre-market trading today.

    Broadway Fin Cp (BYFC) jumped over 46.88% at $2.82 in pre-market ‎trading on Tuesday after the company and CFBanc Corporation revealed receipt of regulatory approvals for the merger.

    Top Upgrades & Downgrades


    Needham turned bullish on Merit Medical Systems Inc. (MMSI), upgrading the stock to “Buy” and assigning a $65.0 price target, representing potential upside of 18.69% from Monday’s close.
     

    DocuSign Inc. (DOCU) has won the favor of Piper Sandler’s equity research team. The firm upgraded the shares from Neutral to Overweight and moved their price target to $300.
     

    Cadence Design Systems Inc. (CDNS) received an upgrade from analysts at KeyBanc, who also set their one-year price target on the stock to $155.0. They changed their rating on CDNS to Overweight from Sector Weight in a recently issued research note.
     

    Earlier Sunday Piper Sandler reduced its rating on Fortinet Inc. (FTNT) stock to Neutral from Overweight.
     

    Piper Sandler analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Rapid7 Inc. (RPD) has been changed to Neutral from Overweight and the new price target is set at $95.
     

    Analysts at Piper Sandler downgraded Okta Inc. (OKTA)’s stock to Neutral from Overweight on Tuesday.

    Latest Insider Activity

    ReneSola Ltd (SOL) CFO SHAH CAPITAL MANAGEMENT announced the sale of shares taking place on Dec 31 at $11.90 for some 26,000 shares. The total came to more than $0.31 million.
     

    ACM Research Inc. (ACMR) Wang Jian sold on Dec 30 a total 84,386 shares at $78.00 on average. The insider’s sale generated proceeds of almost $2.53 million.
     

    Hall of Fame Resort & Entertainment Company (HOFV) Director Lichter Stuart declared the purchase of shares taking place on Dec 29 at $1.40 for some 10,813,774 shares. The transaction amount was around $15.14 million.
     

    Beyond Air Inc. (XAIR) CEO, Chairman Lisi Steven A. bought on Dec 31 a total 929 shares at $5.28 on average. The purchase cost the insider an estimated $203,280.

    Important Earnings

    Top US earnings releases scheduled for today include Cal-Maine Foods Inc. (NASDAQ:CALM). It will announce its Nov 2020 financial results. The company is expected to report earnings of -$0.08 per share from revenues of $333.49M in the three-month period.

  • 23 Stocks Making Sharp Moves in Pre Market Session

    23 Stocks Making Sharp Moves in Pre Market Session

    ‎Bionano Genomics Inc. (BNGO) stock soared 46.62% to $1.95 in the pre-‎market ‎trading after reporting that Praxis Genomics, LLC received accreditation from the College of ‎American ‎Pathologists (CAP). The most recent rating by Ladenburg Thalmann, on September 24, 2020, ‎is a Buy.‎

    ‎Tenax Therapeutics Inc. (NASDAQ: TENX) shares are trading down -7.07% at $1.84 ‎at ‎the time of writing. Company’s 52-week ranged between $0.25 to $2.68.‎

    ‎Ideanomics Inc. (IDEX) stock soared 2.87% to $2.15 in the pre-market trading. ‎The ‎company recently revealed that its Mobile Energy Global (“MEG”) and its contracting entity ‎Qingdao ‎Chengyang Medici have signed an agreement with Meihao Chuxing, a joint venture between ‎BYD and ‎Didi, to purchase an initial 2,000 units of model BYD D1. ‎

    ‎Oxbridge Re Holdings Limited (OXBR) stock moved down -6.83 percent to $1.91 ‎in ‎the pre-market trading.‎

    ‎Guardion Health Sciences Inc. (NASDAQ: GHSI) shares are trading up 12.48% ‎at ‎‎$0.4289 at the time of writing. The firm lately declared the appointment of seasoned ‎nutritional ‎products industry leader Bret Scholtes as President and Chief Executive Officer. Company’s ‎‎52-week ‎ranged between $0.17 to $0.74.‎

    ‎Gevo Inc. (GEVO) is down more than -4.76% at $4.4 in pre-market ‎hours ‎Wednesday December 30, 2020. The stock had dropped over -4.15% to $4.62 in the last ‎trading ‎session.‎

    ‎Universal Security Instruments Inc. (UUU) stock moved up 5.0 percent to $5.25 ‎in ‎the pre-market trading following its statement regarding recent market activity in the ‎Company’s ‎stock.‎

    ‎Marathon Patent Group Inc. (MARA) gained over 10.03% at $12.94 in pre-‎market ‎trading Wednesday December 30, 2020. The company recently reported that it has entered ‎into a ‎contract with Bitmain to purchase 70,000 Antminer S-19 ASIC miners.‎

    Before the trading started on December 30, 2020, Ocugen Inc. (OCGN) is down -‎‎‎7.83% to reach $2.0. It has been trading in a 52-week range of $0.17 to $3.05.‎

    Before the trading started on December 30, 2020, Moderna Inc. (MRNA) is ‎up ‎‎3.59% to reach $118.5 following the declaration from the company that the it is engaged in ‎discussions ‎with the government of South Korea to potentially provide 40 million or more doses of the ‎Moderna ‎COVID-19 Vaccine to support South Korea’s aim of providing vaccines to the public as soon as ‎possible. ‎It has been trading in a 52-week range of $17.68 to $178.50.‎

    ‎Riot Blockchain Inc. (RIOT) stock soared 6.02% to $16.74 in the pre-market trading.‎

    ‎Technical Communications Corporation (NASDAQ: TCCO) shares are trading down -‎‎‎16.78% at $4.76 at the time of writing after declaring its results for the fiscal year ended September ‎‎26, ‎‎2020. Company’s 52-week ranged between $1.72 to $7.00.‎

    ‎Tonix Pharmaceuticals Holding Corp. (TNXP) is up more than 2.21% at $0.6695 ‎in ‎pre-market hours Wednesday December 30, 2020. The stock had dropped over -6.16% to $0.65 in ‎the ‎last trading session.‎

    ‎AstraZeneca PLC (AZN) gained over 2.26% at $51.03 in pre-market ‎trading ‎Wednesday December 30, 2020 after receiving approval of its coronavirus vaccine in U.K.‎

    ‎New Concept Energy Inc. (AMEX: GBR) shares are trading down -14.75% at $2.08 ‎at ‎the time of writing. Company’s 52-week ranged between $0.55 to $2.19.‎

    ‎Moleculin Biotech Inc. (MBRX) stock plunged -1.67% to $0.8279 in the pre-‎market ‎trading after declaring that that the US Food and Drug Administration (FDA) has granted ‎Orphan Drug ‎Designation (ODD) to Annamycin for treatment of soft tissue sarcomas.‎

    ‎MoSys Inc. (MOSY), a Semiconductors company, dropped about -13.22% at $2.1 ‎in ‎pre-market trading Wednesday.‎

    Before the trading started on December 30, 2020, Greenpro Capital Corp. (GRNQ) ‎is ‎down -2.15% to reach $1.82. The company lately revealed that it intends to set up a Bitcoin ‎‎($BTC) ‎Fund for investment. It has been trading in a 52-week range of $0.21 to $3.12.‎

    ‎Nxt-ID Inc. (NXTD) gained over 9.92% at $1.44 in pre-market trading ‎Wednesday ‎December 30, 2020.‎

    ‎Hepion Pharmaceuticals Inc. (HEPA) gained over 50.0% at $3.12 in pre-‎market ‎trading Wednesday December 30, 2020 after declaring positive top line data for low dose ‎CRV431 in ‎Phase 2a ‘AMBITION’ clinical trial for treatment of Advanced NASH.‎

    ‎XPeng Inc. (XPEV) is up more than 3.13% at $42.85 in pre-market hours ‎Wednesday ‎December 30, 2020. The stock had jumped over 9.31% to $41.55 in the last trading session.‎

    ‎BioNTech SE (BNTX) is up more than 3.5% at $91.37 in pre-market hours ‎Wednesday ‎December 30, 2020 following declaration from the financial magazine Caixin that Shanghai ‎Fosun ‎Pharmaceutical Group will set up a joint venture with BioNTech to produce COVID-19 vaccines in ‎China. ‎The stock had jumped over 0.19% to $88.28 in the last trading session.‎

    Before the trading started on December 30, 2020, Bit Digital Inc. (BTBT) is up ‎‎14.58% ‎to reach $12.1. It has been trading in a 52-week range of $0.28 to $12.45.‎

  • Market Movers: What changed for these 21 stocks while you were sleeping

    Market Movers: What changed for these 21 stocks while you were sleeping

    ‎Greenpro Capital Corp. (GRNQ), a Conglomerates company, dropped about -‎‎5.88% ‎at $1.76 in pre-market trading Tuesday after announcing Bitcoin fund.‎

    ‎ATIF Holdings Limited (ATIF) stock plunged -8.51% to $0.9698 in the pre-‎market ‎trading.‎

    ‎Bionano Genomics Inc. (BNGO) stock soared 8.57% to $0.96 in the pre-‎market ‎trading after declaring that Praxis Genomics, LLC received accreditation from the College of ‎American ‎Pathologists (CAP). The most recent rating by Ladenburg Thalmann, on September 24, 2020, ‎is a Buy. ‎

    ‎Zomedica Corp. (AMEX: ZOM) shares are trading up 4.5% at $0.2625 at the ‎time ‎of ‎writing. Company’s 52-week ranged between $0.06 to $0.50.‎

    ‎Nano Dimension Ltd. (NASDAQ: NNDM) shares are trading up 5.52% at $8.6 at ‎the ‎time of writing after pricing $250 million registered direct offering. ‎Company’s 52-week ‎ranged ‎between $0.51 to $10.49. Analysts have a consensus price target of $8. ‎

    ‎Jaguar Health Inc. (JAGX) stock moved down -2.88 percent to $0.7325 in the pre-‎‎market trading.‎

    ‎Ideanomics Inc. (IDEX), a Software – Application company, rose about 4.27% at ‎‎$2.44 ‎in pre-market trading Tuesday following the declaration the signing of an agreement of its ‎Mobile ‎Energy Global (“MEG”) and contracting entity Qingdao Chengyang Medici with Meihao ‎Chuxing, a joint ‎venture between BYD and Didi, to purchase an initial 2,000 units of model BYD D1. ‎

    ‎Alibaba Group Holding Limited (BABA) is up more than 3.64% at $230.45 in pre-‎‎‎market hours Tuesday December 29, 2020. The stock had jumped over 0.16% to $222.36 in ‎the ‎last ‎trading session.‎

    Before the trading started on December 29, 2020, FuelCell Energy Inc. (FCEL) is ‎up ‎‎2.3% to reach $11.81. It has been trading in a 52-week range of $0.84 to $13.91.‎

    ‎AeroCentury Corp. (ACY) lost over -25.7% at $10.29 in pre-market trading ‎Tuesday ‎December 29, 2020 following the update of listing standards compliance.‎

    ‎Color Star Technology Co. Ltd. (CSCW) is down more than -9.21% at $0.69 in pre-‎‎‎market hours Tuesday December 29, 2020. The stock had jumped over 7.04% to $0.76 in ‎the ‎last ‎trading session.‎

    Before the trading started on December 29, 2020, Guardion Health Sciences ‎Inc. ‎‎(GHSI) is up 14.83% to reach $0.36. The firm recently reported the appointment of ‎Bret ‎Scholtes, as its President and Chief Executive Officer, and as a member of the Board of Directors. ‎He is ‎a veteran of the nutritional products industry for nearly a decade. It has been trading in a 52-‎week ‎range of $0.17 to $0.74.‎

    ‎Nokia Corporation (NOK) stock soared 2.31% to $3.99 in the pre-market ‎trading ‎after reporting that it has been selected by Thailand’s dtac as its first 5G partner.‎ The most ‎recent ‎rating by Exane BNP Paribas, on October 30, 2020, is a Neutral. ‎

    Before the trading started on December 29, 2020, Acasti Pharma Inc. (ACST) is ‎up ‎‎7.32% to reach $0.3343. It has been trading in a 52-week range of $0.17 to $2.75.‎

    ‎RMG Acquisition Corp. (RMG) grew over 2.1% at $32.61 in pre-market trading ‎today ‎following the stockholder approval of business combination with Romeo Systems, Inc. with ‎no ‎redemptions.‎

    ‎Aprea Therapeutics Inc. (APRE), a Biotechnology company, rose about 4.73% ‎at ‎‎$5.76 in pre-market trading Tuesday after declaring results of primary endpoint from Phase 3 trial ‎of ‎Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS).‎

    ‎MicroVision Inc. (NASDAQ: MVIS) shares are trading up 6.41% at $7.14 at ‎the ‎time ‎of writing. Company’s 52-week ranged between $0.15 to $9.74. Analysts have a consensus ‎price ‎target ‎of $4.50.‎

    ‎China Recycling Energy Corporation (CREG) is down more than -2.23% at $5.7 in pre-‎‎market hours Tuesday December 29, 2020 after revealing that it has entered into agreement to ‎acquire ‎Xi’an Taiying Energy Saving Technology ‎Co., Ltd..‎. The stock had jumped over 31.31% to $5.83 in ‎the last ‎trading session. ‎

    ‎BIOLASE Inc. (BIOL) stock moved up 25.44 percent to $0.6021 in the pre-‎market ‎trading.‎

    ‎Borr Drilling Limited (BORR), a Oil & Gas Drilling company, rose about 4.66% ‎at ‎‎$0.854 in pre-market trading Tuesday after reporting the appointment of Mr. Magnus Vaaler as its ‎new ‎Chief Financial Officer. He will replace Mr. Christoph Bausch.‎

    ‎Onconova Therapeutics Inc. (NASDAQ: ONTX) shares are trading up 3.68% ‎at ‎‎$0.465 ‎at the time of writing. Company’s 52-week ranged between $0.19 to $1.56. Analysts have ‎a ‎consensus ‎price target of $7.50.‎